Sarepta Therapeutics Faces Setback After Patient Death Linked to Gene Therapy Treatment

Sarepta Therapeutics Faces Setback After Patient Death Linked to Gene Therapy Treatment
1 month ago

In a developing story within the biotech sector, Sarepta Therapeutics has seen a notable decline in its stock value following reports of a patient death associated with its gene therapy treatment. The company specializes in precision genetic medicine for rare diseases, notably Duchenne Muscular Dystrophy (DMD). This unexpected event has raised concerns among investors and regulators, prompting a thorough investigation.

Continue reading
FDA Drug Approval Process Under Scrutiny: Insights from Biogen and Sarepta's Rapid Approvals

FDA Drug Approval Process Under Scrutiny: Insights from Biogen and Sarepta's Rapid Approvals
3 months ago

The recent approvals of drugs from Biogen and Sarepta have sparked significant debate regarding the Federal Drug Administration's (FDA) regulatory processes, raising questions about the thoroughness and consistency of drug reviews. A detailed report indicates that these swift approvals may highlight gaps within the FDA's existing frameworks.

Continue reading